Eiger BioPharmaceuticals (EIGRQ) 10-Q 14 Aug 23 2023 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2023	Aug. 09, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity File Number	001-36183
Entity Registrant Name	Eiger BioPharmaceuticals, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	33-0971591
Entity Address, Address Line One	2155 Park Boulevard
Entity Address, City or Town	Palo Alto
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94306
City Area Code	650
Local Phone Number	272-6138
Title of 12(b) Security	Common Stock (par value $0.001 per share)
Trading Symbol	EIGR
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		44,296,417
Amendment Flag	false
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001305253
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 22,983	$ 25,798
Short-term debt securities	30,626	73,150
Accounts receivable, net	3,715	1,749
Inventories	1,098	2,853
Prepaid expenses and other current assets	12,062	13,985
Total current assets	70,484	117,535
Property and equipment, net	755	696
Operating lease right-of-use assets	329	561
Other assets	790	1,347
Total assets	72,358	120,139
Current liabilities:
Accounts payable	4,946	8,975
Accrued liabilities	11,446	15,655
Current portion of operating lease liabilities	321	491
Total current liabilities	16,713	25,121
Debt	40,349	39,625
Operating lease liabilities	1	83
Total liabilities	57,063	64,829
Stockholders’ equity:
Common stock	44	44
Additional paid-in capital	496,087	492,759
Accumulated other comprehensive loss	(164)	(300)
Accumulated deficit	(480,672)	(437,193)
Total stockholders’ equity	15,295	55,310
Total liabilities and stockholders’ equity	$ 72,358	$ 120,139

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenues [Abstract]
Product revenue, net	$ 4,643,000	$ 4,091,000	$ 8,761,000	$ 6,764,000
Costs and operating expenses:
Cost of sales		151,000		261,000
Cost of sales	(310,000)		(192,000)
Research and development	19,401,000	16,993,000	36,149,000	34,563,000
Selling, general and administrative	5,533,000	7,027,000	15,048,000	13,840,000
Total costs and operating expenses	24,624,000	24,171,000	51,005,000	48,664,000
Loss from operations	(19,981,000)	(20,080,000)	(42,244,000)	(41,900,000)
Interest expense	(1,343,000)	(934,000)	(2,628,000)	(1,820,000)
Interest income	660,000	221,000	1,371,000	266,000
Other (expense) income, net	(29,000)	(1,074,000)	26,000	(1,047,000)
Loss before provision for income taxes	(20,693,000)	(21,867,000)	(43,475,000)	(44,501,000)
Provision for income taxes	2,000	17,000	4,000	26,000
Net loss	$ (20,695,000)	$ (21,884,000)	$ (43,479,000)	$ (44,527,000)
Net loss per common share:
Basic (in USD per share)	$ (0.47)	$ (0.51)	$ (0.98)	$ (1.14)
Diluted (in USD per share)	$ (0.47)	$ (0.51)	$ (0.98)	$ (1.14)
Weighted-average common shares outstanding:
Basic (in shares)	44,296,417	43,059,809	44,221,442	39,178,043
Diluted (in shares)	44,296,417	43,059,809	44,221,442	39,178,043
Product revenue, net
Revenues [Abstract]
Product revenue, net	$ 4,393,000	$ 3,341,000	$ 8,511,000	$ 6,014,000
Other revenue
Revenues [Abstract]
Product revenue, net	$ 250,000	$ 750,000	$ 250,000	$ 750,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Statement of Comprehensive Income [Abstract]
Net loss	$ (20,695)	$ (21,884)	$ (43,479)	$ (44,527)
Other comprehensive loss:
Unrealized (loss) gain on available-for-sale debt securities, net	(7)	(239)	160	(612)
Foreign currency translation adjustment	13	0	(24)	0
Comprehensive loss	$ (20,689)	$ (22,123)	$ (43,343)	$ (45,139)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive (Loss)	Accumulated Deficit
Balance, beginning of period (in shares) at Dec. 31, 2021		34,568,821
Balance, beginning of period at Dec. 31, 2021	$ 72,399	$ 35	$ 412,930	$ (149)	$ (340,417)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)		5,841,786
Issuance of common stock	45,610	$ 6	45,604
Issuance of common stock upon exercise of stock options (in shares)		15,995
Issuance of common stock upon exercise of stock options	144		144
Vesting of common stock issued under Product Development Agreement	19		19
Issuance of common stock upon ESPP purchase (in shares)		18,130
Issuance of common stock upon ESPP purchase	64		64
Issuance of common stock upon release of restricted stock units (in shares)		85,106
Stock-based compensation expense	2,047		2,047
Unrealized gain/(loss) on available-for-sale debt securities, net	(373)			(373)
Net loss	(22,643)				(22,643)
Balance, end of period (in shares) at Mar. 31, 2022		40,529,838
Balance, end of period at Mar. 31, 2022	97,267	$ 41	460,808	(522)	(363,060)
Balance, beginning of period (in shares) at Dec. 31, 2021		34,568,821
Balance, beginning of period at Dec. 31, 2021	72,399	$ 35	412,930	(149)	(340,417)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Unrealized gain/(loss) on available-for-sale debt securities, net	(612)
Cumulative translation adjustment	0
Net loss	(44,527)
Balance, end of period (in shares) at Jun. 30, 2022		43,966,783
Balance, end of period at Jun. 30, 2022	102,925	$ 44	488,586	(761)	(384,944)
Balance, beginning of period (in shares) at Mar. 31, 2022		40,529,838
Balance, beginning of period at Mar. 31, 2022	97,267	$ 41	460,808	(522)	(363,060)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)		2,686,288
Issuance of common stock	20,564	$ 2	20,562
Issuance of common stock upon exercise of stock options (in shares)		1,604
Issuance of common stock upon exercise of stock options	9		9
Issuance of common stock to lender (in shares)		749,053
Issuance of common stock to lender	5,000	$ 1	4,999
Stock-based compensation expense	2,208		2,208
Unrealized gain/(loss) on available-for-sale debt securities, net	(239)			(239)
Cumulative translation adjustment	0
Net loss	(21,884)				(21,884)
Balance, end of period (in shares) at Jun. 30, 2022		43,966,783
Balance, end of period at Jun. 30, 2022	102,925	$ 44	488,586	(761)	(384,944)
Balance, beginning of period (in shares) at Dec. 31, 2022		44,074,284
Balance, beginning of period at Dec. 31, 2022	55,310	$ 44	492,759	(300)	(437,193)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon ESPP purchase (in shares)		29,986
Issuance of common stock upon ESPP purchase	41		41
Issuance of common stock upon release of restricted stock units (in shares)		192,147
Stock-based compensation expense	2,542		2,542
Unrealized gain/(loss) on available-for-sale debt securities, net	167			167
Cumulative translation adjustment	(37)			(37)
Net loss	(22,784)				(22,784)
Balance, end of period (in shares) at Mar. 31, 2023		44,296,417
Balance, end of period at Mar. 31, 2023	35,239	$ 44	495,342	(170)	(459,977)
Balance, beginning of period (in shares) at Dec. 31, 2022		44,074,284
Balance, beginning of period at Dec. 31, 2022	55,310	$ 44	492,759	(300)	(437,193)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Unrealized gain/(loss) on available-for-sale debt securities, net	160
Cumulative translation adjustment	(24)
Net loss	(43,479)
Balance, end of period (in shares) at Jun. 30, 2023		44,296,417
Balance, end of period at Jun. 30, 2023	15,295	$ 44	496,087	(164)	(480,672)
Balance, beginning of period (in shares) at Mar. 31, 2023		44,296,417
Balance, beginning of period at Mar. 31, 2023	35,239	$ 44	495,342	(170)	(459,977)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	745		745
Unrealized gain/(loss) on available-for-sale debt securities, net	(7)			(7)
Cumulative translation adjustment	13			13
Net loss	(20,695)				(20,695)
Balance, end of period (in shares) at Jun. 30, 2023		44,296,417
Balance, end of period at Jun. 30, 2023	$ 15,295	$ 44	$ 496,087	$ (164)	$ (480,672)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2022	Mar. 31, 2022
Statement of Stockholders' Equity [Abstract]
Stock issuance costs	$ 716	$ 1,288

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flow (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Operating activities
Net loss	$ (43,479)	$ (44,527)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	140	146
Inventory write down	10	0
Amortization of debt securities premiums and discounts	(778)	564
Loss on extinguishment of debt	0	1,144
Non-cash interest expense	724	468
Reduction in the carrying amount of right-of-use assets	232	268
Common stock issued under Product Development Agreement	0	19
Stock-based compensation	3,287	4,255
Change in operating assets and liabilities:
Accounts receivable	(1,959)	1,538
Inventories	3,171	(330)
Prepaid expenses and other current assets	1,370	(2,636)
Other assets	1,110	(568)
Accounts payable	(3,955)	1,899
Accrued liabilities	(5,661)	(2,138)
Operating lease liabilities	(252)	(305)
Net cash used in operating activities	(46,040)	(40,203)
Investing activities
Purchase of debt securities available-for-sale	(19,388)	(45,779)
Proceeds from maturities of debt securities available-for-sale	62,850	23,239
Purchase of property and equipment	(233)	(9)
Net cash provided by (used in) investing activities	43,229	(22,549)
Financing activities
Issuance of common stock upon offering at-the-market, net of commissions	0	66,402
Proceeds from issuance of common stock to lender	0	5,000
Proceeds from issuance of common stock upon stock option exercises	0	153
Proceeds from issuance of common stock upon ESPP purchase	41	64
Proceeds from debt	0	39,840
Repayment of debt	0	(33,277)
Payment of debt issuance costs	0	(835)
Common stock offering costs	(22)	(244)
Net cash provided by financing activities	19	77,103
Effect of foreign exchange on cash and cash equivalents	(23)	0
Net (decrease) increase in cash and cash equivalents	(2,815)	14,351
Cash and cash equivalents at beginning of period	25,798	22,221
Cash and cash equivalents at end of period	22,983	36,572
Supplemental disclosure of cash flow information:
Interest paid	1,903	1,395
Income taxes paid	148	152
Purchases of property and equipment in accounts payable and accrued liabilities	$ 0	$ 49

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business Eiger BioPharmaceuticals, Inc. (the Company or Eiger) was incorporated in the State of Delaware on November 6, 2008. Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases. Eiger’s lead product candidate, avexitide, is a well characterized, first-in-class glucagon-like peptide-1 ( GLP-1) antagonist and is in development for the treatment of post-bariatric hypoglycemia (PBH) and other form of hyperinsulinemic hypoglycemia (HH) arising after gastrointestinal surgeries. These disorders are characterized by exaggerated secretion of GLP-1 after meals, dysregulated secretion of insulin, and a rapid drop in blood sugar. Avexitide is the only drug in development for PBH with Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA). Avexitide is also in development for congenital hyperinsulinism (HI), an ultra-rare, life-threatening, pediatric disorder of persistent hypoglycemia that results in irreversible brain damage in up to 50% of children with the condition. Avexitide has completed Phase 2 for both PBH and HI, and Phase 3 study startup activities for PBH and for HI have been initiated. The FDA approved the Company’s first commercial product, Zokinvy ® (lonafarnib), to reduce risk of mortality of Hutchinson-Gilford progeria syndrome (HGPS) and for treatment of processing-deficient progeroid laminopathies (PL), with either heterozygous LMNA mutation with progerin-like protein accumulation, or homozygous or compound heterozygous ZMPSTE24 mutations, on November 20, 2020. Collectively known as progeria, HGPS and PL are ultra-rare, fatal, genetic premature aging diseases that accelerate mortality in young patients. In July 2022, the Company announced that the European Commission (EC) granted Eiger a centralized marketing authorization (MA) under the exceptional circumstances procedure for Zokinvy. The EC's centralized MA is valid in all 27 European Union (EU) member states plus Iceland, Liechtenstein, and Norway. In August 2022, the Medicine and Healthcare products Regulatory Agency (MHRA) granted approval in the UK. The Company commercially launched Zokinvy in the U.S. in January 2021 and started to record product revenue in the first quarter of 2021. The first European sales were recognized in the fourth quarter of 2022. In June 2023, the Company announced that it is focusing its clinical development efforts on advancing avexitide in HH indications, including PBH. The Company will continue to commercialize Zokinvy (lonafarnib) for the treatment of HGPS and processing-deficient PL. In addition, Eiger is evaluating strategic partnering options for its virology assets, lonafarnib and peginterferon lambda. In June 2023, the Company also announced that it has appointed David Apelian, MD, PhD, MBA, who has served as interim Chief Executive Officer (CEO) since December 2022, as the Company's next CEO. The Company’s principal operations are based in Palo Alto, California, with subsidiaries in Delaware, Ireland, England and Wales. The Company operates in one segment. Liquidity As of June 30, 2023, the Company had $53.6 million of cash, cash equivalents and short-term securities, comprised of $23.0 million of cash and cash equivalents and $30.6 million of short-term debt securities available-for-sale. The Company had an accumulated deficit of $480.7 million and negative cash flows from operating activities as of June 30, 2023. As the Company continues to incur losses, its transition to profitability will depend on the successful development, approval, and commercialization of product candidates and on the achievement of sufficient revenues to support its cost structure. The Company may never achieve profitability, and until it does, the Company will need to continue to raise additional capital, including by potentially drawing the $17.5 million available under Tranche B under Innovatus Term Loan. Management believes that the currently available resources will be sufficient to fund its planned operations for at least the next 12 months following the issuance date of these condensed consolidated financial statements. However, if the Company’s anticipated operating results are not achieved in future periods, the Company believes that planned expenditures may need to be reduced or it would be required to raise funding in order to fund the operations. Additionally, the Company’s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and disruptions to, and volatility in, the credit and financial markets in the United States and worldwide.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The condensed consolidated financial statements include the accounts of Eiger BioPharmaceuticals, Inc. and its wholly owned subsidiaries, EBPI Merger Inc., EB Pharma LLC, Eiger BioPharmaceuticals Europe Limited, and EigerBio Europe Limited, have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and follow the requirements of the Securities and Exchange Commission (SEC) for annual reporting. All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates. Concentrations of Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and investments. The Company’s cash is held by financial institutions in the United States and Ireland. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institutions are financially sound, and accordingly, minimal credit risk exists with respect to the financial institutions. The Company relies on one supply chain for each of its product candidates. If any of the single source suppliers in any of the supply chains fail to satisfy the Company’s requirements on a timely basis, it could suffer delays in its clinical development programs and activities which could adversely affect its operating results. Two customers accounted for approximately 63 percent and 37 percent of the Company’s accounts receivable as of June 30, 2023. Two customers accounted for approximately 58 percent and 42 percent of the Company’s accounts receivable as of December 31, 2022. Two customers accounted for approximately 78 percent and 22 percent of product revenue during the three months ended June 30, 2023. Two customers accounted for approximately 77 percent and 23 percent of product revenue during the six months ended June 30, 2023. One customer accounted for approximately 99 percent and 100 percent of product revenue during the three and six months ended June 30, 2022. Three vendors accounted for approximately 43 percent, 12 percent and 11 percent of the Company's accounts payable as of June 30, 2023. Two vendors accounted for approximately 12 percent and 11 percent of the Company's accounts payable as of December 31, 2022. Foreign Currency Exchange Foreign Currency Transaction Risk The foreign currency transaction risk relates to changes in exchange rates on monetary assets, liabilities, revenues and expenses held at Eiger BioPharmaceuticals Europe Limited . Gains and losses on foreign currency transactions result primarily from monetary assets, liabilities, revenues and expenses denominated in Euro. Aggregated transaction gains for the six months ended June 30, 2023 was $26,000 and the aggregated transaction loss for the three months ended June 30, 2023 was $29,000. The Company expects the foreign currency gain/loss to continue to fluctuate as long as the Company continue to hold monetary assets and liabilities at its subsidiaries in Ireland and England and Wales. Market uncertainty could potentially lead to significant volatility with foreign currency exchange rates, which could result in additional foreign currency gain/loss. Foreign Currency Translation Risk The foreign currency translation risk relates to the translation of the foreign consolidated subsidiaries' assets, liabilities, revenues and expenses from the subsidiaries’ functional currency to the U.S. dollar at each reporting date. Fluctuations in exchange rates may impact the amount of assets, liabilities, revenues and expenses reported on the consolidated balance sheets and consolidated statements of operations. The financial statements of the Company’s foreign subsidiaries, which have a functional currency other than the U.S. dollar, are translated into U.S. dollars using a current exchange rate. Gains and losses resulting from this translation are recognized as a foreign currency translation adjustment within accumulated other comprehensive loss, which is a component of stockholders' equity and comprehensive income (loss). Aggregate translation gain, net of tax, was $13,000 and $0 for the three months ended June 30, 2023 and 2022, respectively, and aggregated translation loss, net of tax was $24,000 and $0 for the six months ended June 30, 2023 and 2022, respectively. Debt Securities All securities are short-term in nature and consist of debt securities classified as available-for-sale and have maturities greater than 90 days, but less than 365 days from the date of acquisition. The Company’s debt securities consist of available-for-sale securities that are classified as Level 2 because their value is based on valuations using significant inputs derived from, or corroborated by, observable market data. The Company evaluates, on a quarterly basis, its available-for-sale debt securities for potential impairment. For available-for-sale debt securities in an unrealized loss position, the Company assesses whether such declines are due to credit related factors such as changes to the rating of the security by a ratings agency, market conditions and supportable forecasts of economic and market conditions, among others. If the fair value of available-for-sale debt securities is less than the amortized cost basis, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any available-for-sale debt security before recovery of its amortized cost basis. If either condition is met, the security’s amortized cost basis is written down to fair value and is recognized through other (expense) income, net. If neither condition is met, declines as a result of credit losses, if any, are recognized as an allowance for credit loss, limited to the amount of unrealized loss, through other (expense) income, net. Any portion of the unrealized loss that is not a result of a credit loss, is recognized in other comprehensive loss. The cost of available-for-sale securities sold is based on the specific-identification method . Realized gains and losses on the sale of debt securities are determined using the specific-identification method and recorded in other (expense) income, net. Accounts Receivable Accounts receivable represent amounts billed to the Company’s customers, net of an allowance for credit losses. Trade accounts receivable are recorded at invoiced amounts and do not bear interest. The allowance for credit losses reflects the Company’s best estimate of probable losses inherent in the receivable portfolio determined based on various factors, including age of the outstanding invoice, credit quality of the customer, historical experience, current economic conditions, and management’s expectations of future economic conditions. The Company regularly reviews the adequacy of the allowance for credit losses by considering the age of each outstanding invoice and the collection history of each customer to determine the appropriate amount of allowance for credit losses. The Company had no allowance for credit losses as of June 30, 2023 and December 31, 2022. The Company had no credit losses for the periods presented. Inventories Inventories are stated at the lower of cost, determined based on actual costs, or estimated net realizable value, on a first-in, first-out basis. Inventories consist of raw materials, work-in-process, and finished goods. Prior to regulatory approval of the Company’s product candidates, expenses incurred to manufacture drug products are recorded as research and development expense. The Company begins capitalizing these expenses as inventory upon regulatory approval. The Company periodically assesses the recoverability of its inventory and reduces the carrying value of the inventory when items are determined to be obsolete, defective or in excess of forecasted sales requirements. Inventory write-downs for excess, defective, and obsolete inventory are recorded as a cost of sales. The write downs of inventory were immaterial for the three and six months ended June 30, 2023 and 2022. Revenue Recognition The Company recognizes revenue upon transfer of control of promised products to customers in an amount that reflects the consideration it expects to receive in exchange for those products. To determine revenue recognition for contracts with customers, the Company performs the following five-step approach: (i) identify the contract, or contracts, with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the performance obligation is satisfied. The five-step model is only applied to contracts when it is probable that the Company will collect substantially all of the consideration it is entitled to in exchange for the goods transferred to a customer. Product Revenue The Company’s product revenue consists of sales of Zokinvy, which received FDA approval in November 2020, EC centralized MA in July 2022, and MHRA approval in August 2022. Zokinvy was launched commercially in the United States in January 2021 and in Europe in November 2022. In the United States, the Company sells Zokinvy to a single specialty pharmacy provider that subsequently dispenses the product directly to patients. The Company discloses revenue on a total basis without further disaggregation. Additionally, the Company does not have any contract assets or liabilities, other than accounts receivable, related to its product revenue. In June 2021, the French National Agency for Medicines and Health Products Safety (ANSM) granted Zokinvy a Temporary Authorizations for Use (Autorisation Temporaire d'Utilisation or ATU) for an early access program for a term of one year. The Company has received a one year extension through September 2024 of the ATU program and expects the program to continue until commercial reimbursement of Zokinvy is approved in France. In the context of this program, the Company sells product to a distributor who in turn ships product to pharmacies after receiving requests from physicians for patients in France. In November 2021, the Company began distributing and recognizing revenue from sales of Zokinvy through a reimbursed early access program in France. The Company recorded revenue of $0.1 million and $0.6 million from sales of product under the ATU program for the three and six months ended June 30, 2023, respectively. The revenue from sales of product under the ATU program was immaterial for the three and six months ended June 30, 2022. The Company recognizes product revenue when a customer obtains control of its product, which occurs at a point in time, typically upon delivery to a customer as the delivery of the product is the Company’s only performance obligation. Shipping and handling activities are fulfillment activities rather than a separate performance obligation and are recorded in cost of sales. Product revenue is recorded at the net sales price (transaction price), which includes estimates of variable consideration resulting from rebates, prompt payment discounts, co-payment assistance, and returns. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available. The amount of variable consideration may be constrained and is included in the transaction price only to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Product revenue is recorded after considering the impact of the following variable consideration amounts along with the constraint at the time of revenue recognition: Rebates: The Company’s product is subject to government mandated rebates for Medicaid Drug Rebate Program, Medicare Part D Prescription Drug Benefit Program, and other government health care programs in the United States and in Europe. Rebate amounts are based upon contractual agreements or legal requirements with public sector benefit providers. The Company uses the expected-value method for estimating these rebates based on statutory discount rates and expected utilization. The expected utilization of rebates is estimated based on expected coverage of identified patients. Estimates for these rebates are adjusted quarterly to reflect the most recent information. The Company records an accrued liability for unpaid rebates related to products for which control has been transferred to a customer. Prompt payment discounts: The Company provides a discount to a customer if it pays for purchases within 30 days. The Company expects that its customers will earn prompt payment discounts and uses the most likely amount method for estimating such discounts. As a result, when revenues are recognized, the Company deducts the full amount of the prompt payment discounts from total product revenues and records these discounts as a reduction of accounts receivable. Co-payment assistance: The Company provides co-payment assistance to patients who have commercial insurance and meet certain eligibility requirements. The Company uses the expected-value method for estimating co-payment assistance based on estimates of program redemption using data provided by third-party administrators. Estimates for the co-payment assistance are adjusted quarterly to reflect actual experience. The Company records an accrued liability for unredeemed co-payment assistance related to products for which control has been transferred to a customer. Product returns: The Company offers limited product return rights and generally allows for the return of product that is damaged or defective, or within a few months prior to and up to a few months after the product expiration date. The Company considers several factors in the estimation of potential product returns, including expiration dates of the product shipped, the limited product return rights, third-party data in monitoring channel inventory levels, shelf life of the product, and other relevant factors. Other Revenue The Company’s other revenue consists of milestone payments from the Marketing and Distribution Agreement (MDA) with AnGes, Inc., which was executed in May 2022. The agreement provides AnGes with a right to use the Company's intellectual property (IP) and seek regulatory approval for and commercialization of Zokinvy in Japan. The Company will receive additional payments upon achievement of certain regulatory and commercial milestones. Cost of Sales Cost of sales consists primarily of direct and indirect costs related to the manufacturing of Zokinvy for commercial sale, including third-party manufacturing costs, packaging services, freight, storage costs, and write down of inventories. Accrued Research and Development Costs The Company accrues for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical and clinical studies, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued liabilities in the accompanying condensed consolidated balance sheets and within research and development expenses in the accompanying condensed consolidated statements of operations. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. Recent Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Updates (ASU) No. 2016-13, Financial Instruments—Credit Losses (Topic 326) . ASU 2016-13 requires an entity to utilize a new impairment model that requires measurement and recognition of expected credit losses for most financial assets and certain other instruments, including but not limited to available-for-sale debt securities. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. The new guidance requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new guidance. In April 2019, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments – Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, which clarifies and corrects certain unintended applications of the guidance contained in each of the amended Topics. Additionally, in May 2019, the FASB issued ASU No. 2019-05, Financial Instruments – Credit Losses (Topic 326), which provides an option to irrevocably elect to measure certain individual financial assets at fair value instead of amortized cost. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) , which

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Fair value accounting is applied for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). As of June 30, 2023 and December 31, 2022, the carrying amount of cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximated their estimated fair value due to their relatively short maturities. Management believes the terms of its long-term debt reflect current market conditions for an instrument with similar terms and maturity, therefore the carrying value of the Company’s debt approximated its fair value. Assets and liabilities recorded at fair value on a recurring basis in the condensed consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: Level 1 : Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; Level 2 : Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and Level 3 : Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data. The Company’s money market funds are classified as Level 1 because they are valued using quoted market prices. The Company’s debt securities and commercial paper consist of available-for-sale securities and are classified as Level 2 because their value is based on valuations using significant inputs derived from or corroborated by observable market data. There were no assets or liabilities classified as Level 3 as of June 30, 2023 and December 31, 2022. There were no transfers into or out of Level 3 of the fair value hierarchy during the periods presented. The following tables present the fair value hierarchy for assets and liabilities measured at fair value, and summarize the estimated value of the Company’s cash equivalents and debt securities and the gross unrealized holding gains and losses (in thousands): June 30, 2023 Level Amortized cost Unrealized gain Unrealized loss Estimated Fair Cash equivalents: Money market funds 1 $ 20,297 $ — $ — $ 20,297 Total cash equivalents $ 20,297 $ — $ — $ 20,297 Debt securities: Corporate debt securities 2 $ 3,998 $ — $ (1) $ 3,997 U.S. government bonds 2 26,668 — (39) 26,629 Total debt securities $ 30,666 $ — $ (40) $ 30,626 Classified as: Cash equivalents 1 $ 20,297 Short-term debt securities 2 30,626 $ 50,923 December 31, 2022 Level Amortized cost Unrealized gain Unrealized loss Estimated Fair Cash equivalents: Money market funds 1 $ 11,546 $ — $ — $ 11,546 Commercial paper 2 3,968 — — 3,968 Total cash equivalents $ 15,514 $ — $ — $ 15,514 Debt securities: U.S. government bonds 2 $ 39,646 $ 3 $ (86) $ 39,563 Corporate debt securities 2 28,759 — (117) 28,642 Commercial paper 2 4,945 — — 4,945 Total debt securities $ 73,350 $ 3 $ (203) $ 73,150 Classified as: Cash equivalents 1 & 2 $ 15,514 Short-term debt securities 2 73,150 $ 88,664 There were no financial liabilities as of June 30, 2023 and December 31, 2022. During the three and six months ended June 30, 2023, the Company did not recognize any other-than-temporary impairment losses. The Company determined that the decline in fair value of debt securities was not due to credit-related factors, and no allowance for expected credit losses was recorded as of June 30, 2023 .

Balance Sheet Components

Balance Sheet Components	6 Months Ended
	Jun. 30, 2023
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Components	Balance Sheet Components Inventories Inventories consist of the following (in thousands): June 30, December 31, Raw materials $ 279 $ 1,703 Work-in-progress 628 884 Finished goods 191 266 Total inventories $ 1,098 $ 2,853 Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following (in thousands): June 30, December 31, Prepaid contract manufacturing costs $ 1,572 $ 3,542 Short term deposits 4,732 4,542 Prepaid research costs 3,355 2,822 Prepaid insurance 926 586 Prepaid marketing 343 753 Other 1,134 1,740 Total prepaid expenses and other current assets $ 12,062 $ 13,985 Accrued Liabilities Accrued liabilities consist of the following (in thousands): June 30, December 31, Compensation and related benefits $ 3,925 $ 6,167 Contract research costs 1,559 4,188 Contract manufacturing costs 2,016 2,101 Product revenue reserves 1,831 1,373 Data hosting services 1,089 10 Legal fees 702 562 Other 324 1,254 Total accrued liabilities $ 11,446 $ 15,655

Bristol-Meyers Squibb License A

Bristol-Meyers Squibb License Agreement	6 Months Ended
	Jun. 30, 2023
Product Development Agreement [Abstract]
Bristol-Meyers Squibb License Agreement	Bristol-Meyers Squibb License AgreementOn April 20, 2016, the Company and Bristol-Myers Squibb Company (BMS) entered into a License Agreement (the BMS License Agreement) and a Common Stock Purchase Agreement (the BMS Purchase Agreement).Under the BMS License Agreement, BMS granted the Company an exclusive, worldwide, license to research, develop, manufacture, and sell products containing PEG-interferon Lambda-1a (peginterferon lambda or the Licensed Product) for all therapeutic and diagnostic uses in humans and animals. The Company is responsible for the development and commercialization of the Licensed Product at its sole cost and expense. The Company paid BMS $2.0 million and issued 157,587 shares of its common stock at an aggregate fair value of $3.2 million in April 2016. The BMS License Agreement also includes development and regulatory milestone payments totaling $61.0 million and commercial sales milestones of up to $128.0 million. The Company is obligated to pay BMS annual net sales royalties in the range of mid-single to mid-teens, depending on net sales levels. In fourth quarter of 2020, the Company recorded in research and development expense a $3.0 million milestone, triggered on successful demonstration of proof of concept, as defined by the BMS License Agreement, in a Phase 2 clinical trial. In March 2022, the Company recorded a $5.0 million milestone expense in research and development, which was related to the initiation of a Phase 3 clinical trial, as defined under the BMS License Agreement.

Debt

Debt	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Debt	Debt Innovatus Term Loan On June 1, 2022 (Closing Date), the Company entered into a term loan and security agreement (Innovatus Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus), providing for up to $75.0 million funded in three tranches with a maturity date of August 31, 2027. The floating per annum interest rate of the Innovatus Loan is equal to the sum of (a) the greater of (i) the Prime Rate published in the Money Rates section of the Wall Street Journal (or any successor thereto) and (ii) 3.5%, plus (b) 3.75%; provided that, at the election of the Borrower, up to 2.25% of such rate shall be payable in-kind until the third anniversary of the closing date. The Company is required to make monthly interest-only payments through July 1, 2027, after which the Company is required to make monthly amortizing payments, with the remaining balance of the principal plus accrued and unpaid interest due at maturity. 2.25% of the interest is payable in-kind for the first three years of the term by increasing the principal balance. Prepayments of the loan, in whole or in part, will be subject to an early prepayment fee which declines each year until the third anniversary date of the Closing Date, after which no prepayment fee is required. The Company is also required to pay an exit fee upon any payment or prepayment equal to 6.5% of the aggregate principal amount of the tranches funded under the Innovatus Loan. The Innovatus Loan contains customary representations, warranties, events of default, including failure to pay amounts due, breaches of covenants and warranties, material adverse change events, certain cross defaults and judgements, and insolvency, and covenants of the Company and its subsidiaries, including a requirement to maintain a cash balance of not less than 5% of the aggregate principal amount of funded and outstanding loan terms at all times. The Company believes it is in compliance with the terms included with the Innovatus Loan. The Innovatus Loan is secured by perfected first priority liens on the Company's assets, including a commitment by the Company to not allow any liens to be placed upon the Company's intellectual property. The Company was funded $40.0 million in June 2022 on the Closing Date under Tranche A. The remaining $35.0 million is divided into two tranches (Tranche B and Tranche C). The $17.5 million under each of Tranche B and Tranche C will be available for a period commencing on the later of (a) the first date that the Company achieves certain development and regulatory milestones applicable to each Tranche and (b) November 1, 2022. Both Tranche B and Tranche C draw periods end on the earlier of (a) June 30, 2024 or (b) an event of default. The Company is currently eligible to draw the $17.5 million under Tranche B, but has not done so as of June 30, 2023. The Company identified a number of embedded derivatives that require bifurcation from the Innovatus Loan. These embedded features include mandatory prepayment upon an event of default or change in control and contingent rate increases. However, the fair value of these embedded features was deemed to be immaterial on the date of issuance. At each subsequent reporting period, the Company will reassess the fair value of the embedded features and will record a liability if the fair value of the features becomes material. In connection with the issuance of the Innovatus Loan, the Company recorded a debt discount of $0.2 million and capitalized debt issuance costs of $1.1 million. The discount and issuance costs will be amortized over the life of the loan. Interest expense for the Innovatus Loan for the three and six months ended June 30, 2023 was $1.3 million and $2.6 million, respectively, and is inclusive of non-cash amortization of the debt discount and debt issuance costs and accretion of final payment. The carrying amount of the Innovatus Loan approximates fair value. The effective interest rate for the Innovatus Loan was 13.60% as of June 30, 2023. Additionally, in connection with entering into the Innovatus Loan, the Company entered into a Stock Purchase Agreement with Innovatus for the sale of common stock with an aggregate value of $5.0 million. On June 1, 2022, the Company issued 749,053 shares of common stock to Innovatus at a per share purchase price of $6.6751, the preceding five-day volume weighted average price per share. A portion of the loan proceeds were used to repay in full the approximately $33.5 million of aggregate principal amount, unpaid interest, and exit fees in connection with loans outstanding owed to Oxford Finance LLC (the Oxford Loan) by the Company. Oxford Term Loan On June 1, 2022, upon entering into the Innovatus Loan, the Company repaid the Oxford Loan, including (i) the $30.0 million outstanding principal balances, (ii) $0.2 million in accrued and unpaid interest, and (iii) other final payments consisting of $3.3 million, for a total payment of $33.5 million. The Company recorded a loss of $1.1 million on early extinguishment of the debt related to the unamortized debt premium, discount, and cost of issuance, which was recognized as a component of other (expense) income, net in the condensed consolidated statement of operations. The Company accounts for the amortization of the debt discount utilizing the effective interest method. Debt and unamortized discount balances are as follows (in thousands): June 30, December 31, Face value of debt $ 40,985 $ 40,531 Exit fee 2,600 2,600 Unamortized debt discount associated with exit fee, debt issuance costs and loan origination fees (3,236) (3,506) Total debt, net $ 40,349 $ 39,625

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based CompensationIn June 2016, the Company’s Board of Directors adopted and in August 2016 the Company’s stockholders approved the Amended and Restated 2013 Equity Incentive Plan (Restated 2013 Plan). As of June 30, 2023, there were 3,134,441 shares available for grant under the Restated 2013 Plan. During the second quarter of 2021, the Company approved the 2021 Inducement Plan to be used exclusively for grants of awards to individuals that were not previously employees or directors of the Company as a material inducement to such individuals’ entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. As of June 30, 2023, there were 1,495,000 shares remaining and available to be issued under the 2021 Inducement Plan. The following table summarizes stock option activity under the Company’s stock-based compensation plans during the six months ended June 30, 2023 (in thousands, except option and share data): Number of Weighted- Weighted- Aggregate Outstanding as of December 31, 2022 6,143,183 $ 9.00 6.00 $ — Granted 2,461,278 $ 1.44 Forfeited (1,267,693) $ 5.34 Outstanding as of June 30, 2023 7,336,768 $ 7.26 5.16 $ — Vested and exercisable as of June 30, 2023 4,606,523 $ 9.41 3.47 $ — During the three and six months ended June 30, 2023, the weighted-average grant date fair value of options granted were $1.03 and $1.44 per share, respectively. During the three and six months ended June 30, 2022, the weighted-average grant date fair value of options granted were $4.39 and $3.53 per share, respectively. The Company records stock-based compensation of stock options granted by estimating the fair value of stock-based awards using the Black-Scholes option pricing model and amortizes the fair value of the stock-based awards granted over the applicable vesting period of the awards on a straight-line basis. The fair value of stock options was estimated using the following weighted-average assumptions: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Expected term (in years) 6.02 6.08 5.15-6.08 5.27-6.08 Volatility 91.26%-92.98% 70.15%-71.20% 90.21%-93.48% 68.71%-71.20% Risk free interest rate 3.50%-4.05% 2.84%-3.03% 3.50%-4.22% 1.76%-3.03% Dividend yield — — — — Restricted Stock Units and Performance Stock Units There were no performance stock units (PSUs) granted during the three months ended June 30, 2023. During the six months ended June 30, 2023, the Company granted 15,000 PSUs, with a weighted-average grant date fair value of $2.26 per share. During the three and six months ended June 30, 2022, the Company granted 30,000 PSUs with a weighted-average grant date fair value of $6.87 per share for both periods. The performance-based metrics include the achievement of certain revenue targets and clinical and regulatory milestones. During the three and six months ended June 30, 2023, the Company recorded $0.1 million and $0.2 million, respectively, of stock-based compensation expense related to the PSUs as it was expected at the beginning of the period that all milestones would be achieved by the target dates. This expense is included in selling, general and administrative expenses. On June 30, 2023, the Company reassessed the probability of the performance-based metrics being achieved. The Company concluded that the performance-based metrics are no longer probable of being achieved but are still more than improbable. As such, the Company will discontinue recognizing expense related to the PSUs on a prospective basis and will not reverse the previously recognized expenses. In May 2023, four employees were terminated who had outstanding PSU awards. As the performance-based metrics were not achieved at time of termination, the stock compensation expense related to these awards of $0.4 million was reversed. During the three and six months ended June 30, 2022, there were no PSUs vested as the performance-based metrics of the PSUs had not yet been achieved. As of June 30, 2023, other than 15,000 PSUs for which vesting was accelerated in connection with the modification noted below, no PSUs have vested as the performance-based metrics of the PSUs have not yet been achieved. There were no restricted stock units (RSUs) granted during the three months ended June 30, 2023 and 2022. During the six months ended June 30, 2023 and 2022, the Company granted 39,167 and 298,150 RSUs, respectively, with a weighted-average grant date fair value of $2.26 and $5.22 per share, respectively. In relation to the RSUs granted, the Company recognized $0.1 million and $0.5 million in stock-based compensation expense for the three months ended June 30, 2023 and 2022, respectively, and $0.5 million and $0.9 million in stock-based compensation expense for the six months ended June 30, 2023 and 2022, respectively, which were included in selling, general and administrative expenses. As of June 30, 2023, the total unrecognized compensation expense related to unvested RSUs and PSUs was $1.4 million, which the Company expects to recognize over an estimated weighted-average period of 1.7 years. The following table summarizes RSU and PSU activity and weighted average grant date fair value for the six months ended June 30, 2023: Shares Weighted- Unvested shares as of December 31, 2022 641,407 $ 7.08 Granted 54,167 $ 2.26 Vested (192,147) $ 5.12 Forfeited (202,019) $ 7.23 Unvested shares as of June 30, 2023 301,408 $ 7.36 Awards Modification On February 6, 2023, the Company entered into a separation agreement and general release with David Cory, the Company's former President and CEO. Pursuant to the separation agreement, 50% of Mr. Cory's unvested equity awards were accelerated to vest on the date the separation agreement was executed. Additionally, the exercise period for Mr. Cory's vested awards was extended, including his accelerated awards. The stock compensation recognized related to these modifications was $0 and $0.9 million for the three and six months ended June 30, 2023, which is reflected in selling, general and administrative expenses. Stock-Based Compensation Expense Total stock-based compensation expense recognized was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Research and development $ 517 $ 820 $ 1,351 $ 1,445 Selling, general and administrative 228 1,388 1,936 2,810 Total $ 745 $ 2,208 $ 3,287 $ 4,255 As of June 30, 2023, the total unrecognized compensation expense related to unvested options was $6.1 million, which the Company expects to recognize over an estimated weighted average period of 2.8 years.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesThe Company’s provision for income taxes was approximately $2,000 and $4,000 for the three and six months ended June 30, 2023, respectively, with an effective tax rate of (0.01)% for the six months ended June 30, 2023. The Company’s provision for income taxes was approximately $17,000 and $26,000 for the three and six months ended June 30, 2022, respectively, with an effective tax rate of (0.06)% for the six months ended June 30, 2022. The effective tax rate in each period differs from the U.S. statutory tax rate primarily due to the valuation allowances on the Company’s deferred tax assets as it is more likely than not that some or all of the Company’s deferred tax assets will not be realized. The tax expense recorded for the three and six months ended June 30, 2023 relates to state taxes.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Commitments and Contingencies	Commitments and Contingencies Lease Agreements In October 2017, the Company entered into a non-cancelable operating facility lease agreement for 8,029 square feet of office space located at 2155 Park Boulevard in Palo Alto, California. The lease commenced on March 1, 2018 and was to expire in February 2023. The lease had a three-year renewal option prior to expiration. The lease included rent escalation clauses throughout the lease term. In October 2017, the Company provided a security deposit of $0.3 million. In February 2023, the Company amended the lease to extend the lease by one year with a one year renewal option. The extended lease commenced on March 1, 2023 and expires on February 28, 2024. The Company accounted for the amendment as a lease modification in accordance with ASC Topic 842. The Company also has additional operating leases that are included in its lease accounting but are not considered material for disclosure. The maturities of the Company’s operating lease liabilities as of June 30, 2023 were as follows (in thousands): Undiscounted lease payments June 30, 2023 Remaining in 2023 $ 249 2024 84 2025 1 Total undiscounted payments 334 Less: imputed interest 12 Present value of future lease payments 322 Less: current portion of operating lease liabilities 321 Operating lease liabilities $ 1 Rent expense recognized for the Company’s operating leases was $0.1 million for the three months ended June 30, 2023 and 2022, and $0.3 million for the six months ended June 30, 2023 and 2022. Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments for the operating leases were $23,000 for the three months ended June 30, 2023 and 2022, and $38,000 and $46,000 for the six months ended June 30, 2023 and 2022, respectively. The operating cash outflows for the operating lease liabilities were $0.3 million for the six months ended June 30, 2023 and 2022. As of June 30, 2023 and December 31, 2022, the weighted-average remaining lease terms were 0.7 years and 1.2 years, and weighted-average discount rates were 12.82% and 12.82%, respectively. Legal Matters Schoen v. Eiger BioPharmaceuticals, Inc., et al. , Case No. 22-cv-06985 On November 8, 2022 a putative securities class action complaint was filed in the United States District Court for the Northern District of California alleging that the company and two former executives violated Sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b-5. The complaint alleged generally that between March 2021 and October 2022, material misstatements and omissions were made to shareholders regarding the TOGETHER study of peginterferon lambda for the treatment of COVID-19 as well as the likelihood of FDA approval of an Emergency Use Authorization for peginterferon lambda. The Court appointed a lead plaintiff on March 2, 2023. On April 10, 2023, the lead plaintiff filed a notice of voluntary dismissal without prejudice. The Progeria Research Foundation, Inc. v. Eiger BioPharmaceuticals, Inc. Arbitration On November 15, 2022, the Company received a demand for arbitration (Demand) from claimant The Progeria Research Foundation, Inc. (PRF) asserting two claims under a May 15, 2018 Collaboration and Supply Agreement (the PRF Collaboration Agreement) between the parties. PRF has alleged that the Company breached an obligation to supply quantities of a drug as requested by PRF. PRF also has a claim for declaratory relief regarding the grant of licenses under the PRF Collaboration Agreement. On January 18, 2023, the Company filed a response to the Demand denying PRF’s claims, contesting the arbitrability of PRF’s claim for declaratory relief, and asserting a counterclaim for declaratory relief related to the contractual provision underlying PRF’s original drug supply claim. To give the parties an opportunity to discuss a potential negotiated resolution of their dispute, the arbitration has been suspended through the end of 2023. As a
Commitments and Contingencies	Commitments and Contingencies Lease Agreements In October 2017, the Company entered into a non-cancelable operating facility lease agreement for 8,029 square feet of office space located at 2155 Park Boulevard in Palo Alto, California. The lease commenced on March 1, 2018 and was to expire in February 2023. The lease had a three-year renewal option prior to expiration. The lease included rent escalation clauses throughout the lease term. In October 2017, the Company provided a security deposit of $0.3 million. In February 2023, the Company amended the lease to extend the lease by one year with a one year renewal option. The extended lease commenced on March 1, 2023 and expires on February 28, 2024. The Company accounted for the amendment as a lease modification in accordance with ASC Topic 842. The Company also has additional operating leases that are included in its lease accounting but are not considered material for disclosure. The maturities of the Company’s operating lease liabilities as of June 30, 2023 were as follows (in thousands): Undiscounted lease payments June 30, 2023 Remaining in 2023 $ 249 2024 84 2025 1 Total undiscounted payments 334 Less: imputed interest 12 Present value of future lease payments 322 Less: current portion of operating lease liabilities 321 Operating lease liabilities $ 1 Rent expense recognized for the Company’s operating leases was $0.1 million for the three months ended June 30, 2023 and 2022, and $0.3 million for the six months ended June 30, 2023 and 2022. Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments for the operating leases were $23,000 for the three months ended June 30, 2023 and 2022, and $38,000 and $46,000 for the six months ended June 30, 2023 and 2022, respectively. The operating cash outflows for the operating lease liabilities were $0.3 million for the six months ended June 30, 2023 and 2022. As of June 30, 2023 and December 31, 2022, the weighted-average remaining lease terms were 0.7 years and 1.2 years, and weighted-average discount rates were 12.82% and 12.82%, respectively. Legal Matters Schoen v. Eiger BioPharmaceuticals, Inc., et al. , Case No. 22-cv-06985 On November 8, 2022 a putative securities class action complaint was filed in the United States District Court for the Northern District of California alleging that the company and two former executives violated Sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b-5. The complaint alleged generally that between March 2021 and October 2022, material misstatements and omissions were made to shareholders regarding the TOGETHER study of peginterferon lambda for the treatment of COVID-19 as well as the likelihood of FDA approval of an Emergency Use Authorization for peginterferon lambda. The Court appointed a lead plaintiff on March 2, 2023. On April 10, 2023, the lead plaintiff filed a notice of voluntary dismissal without prejudice. The Progeria Research Foundation, Inc. v. Eiger BioPharmaceuticals, Inc. Arbitration On November 15, 2022, the Company received a demand for arbitration (Demand) from claimant The Progeria Research Foundation, Inc. (PRF) asserting two claims under a May 15, 2018 Collaboration and Supply Agreement (the PRF Collaboration Agreement) between the parties. PRF has alleged that the Company breached an obligation to supply quantities of a drug as requested by PRF. PRF also has a claim for declaratory relief regarding the grant of licenses under the PRF Collaboration Agreement. On January 18, 2023, the Company filed a response to the Demand denying PRF’s claims, contesting the arbitrability of PRF’s claim for declaratory relief, and asserting a counterclaim for declaratory relief related to the contractual provision underlying PRF’s original drug supply claim. To give the parties an opportunity to discuss a potential negotiated resolution of their dispute, the arbitration has been suspended through the end of 2023. As a

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share Basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Since the Company was in a loss position for the three and six months ended June 30, 2023 and 2022, diluted net loss per share is the same as basic net loss per share as the inclusion of all potential common shares outstanding would have been anti-dilutive. Dilutive potential common stock equivalents include the assumed exercise, vesting and issuance of employee stock awards using the treasury stock method. The following table sets forth the outstanding potentially dilutive securities which have been excluded in the calculation of diluted net loss per share because including such securities would be anti-dilutive (in common stock equivalent shares): Three Months Ended Six Months Ended 2023 2022 2023 2022 Options to purchase common stock 7,336,768 6,892,009 7,336,768 6,892,009 Restricted and Performance stock units (unvested) 301,408 818,019 301,408 818,019 ESPP 345,352 89,662 345,352 89,662 Total 7,983,528 7,799,690 7,983,528 7,799,690

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Pay vs Performance Disclosure
Net loss	$ (20,695)	$ (22,784)	$ (21,884)	$ (22,643)	$ (43,479)	$ (44,527)

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The condensed consolidated financial statements include the accounts of Eiger BioPharmaceuticals, Inc. and its wholly owned subsidiaries, EBPI Merger Inc., EB Pharma LLC, Eiger BioPharmaceuticals Europe Limited, and EigerBio Europe Limited, have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and follow the requirements of the Securities and Exchange Commission (SEC) for annual reporting. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.
Concentrations of Risk	Concentrations of Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and investments. The Company’s cash is held by financial institutions in the United States and Ireland. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institutions are financially sound, and accordingly, minimal credit risk exists with respect to the financial institutions. The Company relies on one supply chain for each of its product candidates. If any of the single source suppliers in any of the supply chains fail to satisfy the Company’s requirements on a timely basis, it could suffer delays in its clinical development programs and activities which could adversely affect its operating results.
Foreign Currency Exchange	Foreign Currency Exchange Foreign Currency Transaction Risk The foreign currency transaction risk relates to changes in exchange rates on monetary assets, liabilities, revenues and expenses held at Eiger BioPharmaceuticals Europe Limited . Gains and losses on foreign currency transactions result primarily from monetary assets, liabilities, revenues and expenses denominated in Euro. Aggregated transaction gains for the six months ended June 30, 2023 was $26,000 and the aggregated transaction loss for the three months ended June 30, 2023 was $29,000. The Company expects the foreign currency gain/loss to continue to fluctuate as long as the Company continue to hold monetary assets and liabilities at its subsidiaries in Ireland and England and Wales. Market uncertainty could potentially lead to significant volatility with foreign currency exchange rates, which could result in additional foreign currency gain/loss. Foreign Currency Translation Risk The foreign currency translation risk relates to the translation of the foreign consolidated subsidiaries' assets, liabilities, revenues and expenses from the subsidiaries’ functional currency to the U.S. dollar at each reporting date. Fluctuations in exchange rates may impact the amount of assets, liabilities, revenues and expenses reported on the consolidated balance sheets and consolidated statements of operations. The financial statements of the Company’s foreign subsidiaries, which have a functional currency other than the U.S. dollar, are translated into U.S. dollars using a current exchange rate. Gains and losses resulting from this translation are recognized as a foreign currency translation adjustment within accumulated other comprehensive loss, which is a component of stockholders' equity and comprehensive income (loss). Aggregate translation gain, net of tax, was $13,000 and $0 for the three months ended June 30, 2023 and 2022, respectively, and aggregated translation loss, net of tax was $24,000 and $0 for the six months ended June 30, 2023 and 2022, respectively.
Debt Securities	Debt Securities All securities are short-term in nature and consist of debt securities classified as available-for-sale and have maturities greater than 90 days, but less than 365 days from the date of acquisition. The Company’s debt securities consist of available-for-sale securities that are classified as Level 2 because their value is based on valuations using significant inputs derived from, or corroborated by, observable market data. The Company evaluates, on a quarterly basis, its available-for-sale debt securities for potential impairment. For available-for-sale debt securities in an unrealized loss position, the Company assesses whether such declines are due to credit related factors such as changes to the rating of the security by a ratings agency, market conditions and supportable forecasts of economic and market conditions, among others. If the fair value of available-for-sale debt securities is less than the amortized cost basis, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any available-for-sale debt security before recovery of its amortized cost basis. If either condition is met, the security’s amortized cost basis is written down to fair value and is recognized through other (expense) income, net. If neither condition is met, declines as a result of credit losses, if any, are recognized as an allowance for credit loss, limited to the amount of unrealized loss, through other (expense) income, net. Any portion of the unrealized loss that is not a result of a credit loss, is recognized in other comprehensive loss. The cost of available-for-sale securities sold is based on the specific-identification method . Realized gains and losses on the sale of debt securities are determined using the specific-identification method and recorded in other (expense) income, net.
Accounts Receivable	Accounts Receivable Accounts receivable represent amounts billed to the Company’s customers, net of an allowance for credit losses. Trade accounts receivable are recorded at invoiced amounts and do not bear interest. The allowance for credit losses reflects the Company’s best estimate of probable losses inherent in the receivable portfolio determined based on various factors, including age of the outstanding invoice, credit quality of the customer, historical experience, current economic conditions, and management’s expectations of future economic conditions. The Company regularly reviews the adequacy of the allowance for credit losses by considering the age of each outstanding invoice and the collection history of each customer to determine the appropriate amount of allowance for credit losses.
Inventories	Inventories Inventories are stated at the lower of cost, determined based on actual costs, or estimated net realizable value, on a first-in, first-out basis. Inventories consist of raw materials, work-in-process, and finished goods. Prior to regulatory approval of the Company’s product candidates, expenses incurred to manufacture drug products are recorded as research and development expense. The Company begins capitalizing these expenses as inventory upon regulatory approval.
Revenue Recognition	Revenue Recognition The Company recognizes revenue upon transfer of control of promised products to customers in an amount that reflects the consideration it expects to receive in exchange for those products. To determine revenue recognition for contracts with customers, the Company performs the following five-step approach: (i) identify the contract, or contracts, with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the performance obligation is satisfied. The five-step model is only applied to contracts when it is probable that the Company will collect substantially all of the consideration it is entitled to in exchange for the goods transferred to a customer. Product Revenue The Company’s product revenue consists of sales of Zokinvy, which received FDA approval in November 2020, EC centralized MA in July 2022, and MHRA approval in August 2022. Zokinvy was launched commercially in the United States in January 2021 and in Europe in November 2022. In the United States, the Company sells Zokinvy to a single specialty pharmacy provider that subsequently dispenses the product directly to patients. The Company discloses revenue on a total basis without further disaggregation. Additionally, the Company does not have any contract assets or liabilities, other than accounts receivable, related to its product revenue. In June 2021, the French National Agency for Medicines and Health Products Safety (ANSM) granted Zokinvy a Temporary Authorizations for Use (Autorisation Temporaire d'Utilisation or ATU) for an early access program for a term of one year. The Company has received a one year extension through September 2024 of the ATU program and expects the program to continue until commercial reimbursement of Zokinvy is approved in France. In the context of this program, the Company sells product to a distributor who in turn ships product to pharmacies after receiving requests from physicians for patients in France. In November 2021, the Company began distributing and recognizing revenue from sales of Zokinvy through a reimbursed early access program in France. The Company recorded revenue of $0.1 million and $0.6 million from sales of product under the ATU program for the three and six months ended June 30, 2023, respectively. The revenue from sales of product under the ATU program was immaterial for the three and six months ended June 30, 2022. The Company recognizes product revenue when a customer obtains control of its product, which occurs at a point in time, typically upon delivery to a customer as the delivery of the product is the Company’s only performance obligation. Shipping and handling activities are fulfillment activities rather than a separate performance obligation and are recorded in cost of sales. Product revenue is recorded at the net sales price (transaction price), which includes estimates of variable consideration resulting from rebates, prompt payment discounts, co-payment assistance, and returns. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available. The amount of variable consideration may be constrained and is included in the transaction price only to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Product revenue is recorded after considering the impact of the following variable consideration amounts along with the constraint at the time of revenue recognition: Rebates: The Company’s product is subject to government mandated rebates for Medicaid Drug Rebate Program, Medicare Part D Prescription Drug Benefit Program, and other government health care programs in the United States and in Europe. Rebate amounts are based upon contractual agreements or legal requirements with public sector benefit providers. The Company uses the expected-value method for estimating these rebates based on statutory discount rates and expected utilization. The expected utilization of rebates is estimated based on expected coverage of identified patients. Estimates for these rebates are adjusted quarterly to reflect the most recent information. The Company records an accrued liability for unpaid rebates related to products for which control has been transferred to a customer. Prompt payment discounts: The Company provides a discount to a customer if it pays for purchases within 30 days. The Company expects that its customers will earn prompt payment discounts and uses the most likely amount method for estimating such discounts. As a result, when revenues are recognized, the Company deducts the full amount of the prompt payment discounts from total product revenues and records these discounts as a reduction of accounts receivable. Co-payment assistance: The Company provides co-payment assistance to patients who have commercial insurance and meet certain eligibility requirements. The Company uses the expected-value method for estimating co-payment assistance based on estimates of program redemption using data provided by third-party administrators. Estimates for the co-payment assistance are adjusted quarterly to reflect actual experience. The Company records an accrued liability for unredeemed co-payment assistance related to products for which control has been transferred to a customer. Product returns: The Company offers limited product return rights and generally allows for the return of product that is damaged or defective, or within a few months prior to and up to a few months after the product expiration date. The Company considers several factors in the estimation of potential product returns, including expiration dates of the product shipped, the limited product return rights, third-party data in monitoring channel inventory levels, shelf life of the product, and other relevant factors. Other Revenue The Company’s other revenue consists of milestone payments from the Marketing and Distribution Agreement (MDA) with AnGes, Inc., which was executed in May 2022. The agreement provides AnGes with a right to use the Company's intellectual property (IP) and seek regulatory approval for and commercialization of Zokinvy in Japan. The Company will receive additional payments upon achievement of certain regulatory and commercial milestones.
Cost of Sales	Cost of SalesCost of sales consists primarily of direct and indirect costs related to the manufacturing of Zokinvy for commercial sale, including third-party manufacturing costs, packaging services, freight, storage costs, and write down of inventories.
Accrued Research and Development Costs	Accrued Research and Development Costs The Company accrues for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical and clinical studies, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued liabilities in the accompanying condensed consolidated balance sheets and within research and development expenses in the accompanying condensed consolidated statements of operations. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities.
Recent Adopted Accounting Pronouncements	Recent Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Updates (ASU) No. 2016-13, Financial Instruments—Credit Losses (Topic 326) . ASU 2016-13 requires an entity to utilize a new impairment model that requires measurement and recognition of expected credit losses for most financial assets and certain other instruments, including but not limited to available-for-sale debt securities. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. The new guidance requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new guidance. In April 2019, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments – Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, which clarifies and corrects certain unintended applications of the guidance contained in each of the amended Topics. Additionally, in May 2019, the FASB issued ASU No. 2019-05, Financial Instruments – Credit Losses (Topic 326), which provides an option to irrevocably elect to measure certain individual financial assets at fair value instead of amortized cost. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) , which deferred the effective date for ASU No. 2016-13 for smaller reporting companies to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company adopted this guidance on a modified-retrospective basis effective January 1, 2023 and noted no material impact to the Company’s condensed consolidated financial statements.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Summary of Estimated Value of Cash Equivalents and Debt Securities and Gross Unrealized Holding Gains and Losses	The following tables present the fair value hierarchy for assets and liabilities measured at fair value, and summarize the estimated value of the Company’s cash equivalents and debt securities and the gross unrealized holding gains and losses (in thousands): June 30, 2023 Level Amortized cost Unrealized gain Unrealized loss Estimated Fair Cash equivalents: Money market funds 1 $ 20,297 $ — $ — $ 20,297 Total cash equivalents $ 20,297 $ — $ — $ 20,297 Debt securities: Corporate debt securities 2 $ 3,998 $ — $ (1) $ 3,997 U.S. government bonds 2 26,668 — (39) 26,629 Total debt securities $ 30,666 $ — $ (40) $ 30,626 Classified as: Cash equivalents 1 $ 20,297 Short-term debt securities 2 30,626 $ 50,923 December 31, 2022 Level Amortized cost Unrealized gain Unrealized loss Estimated Fair Cash equivalents: Money market funds 1 $ 11,546 $ — $ — $ 11,546 Commercial paper 2 3,968 — — 3,968 Total cash equivalents $ 15,514 $ — $ — $ 15,514 Debt securities: U.S. government bonds 2 $ 39,646 $ 3 $ (86) $ 39,563 Corporate debt securities 2 28,759 — (117) 28,642 Commercial paper 2 4,945 — — 4,945 Total debt securities $ 73,350 $ 3 $ (203) $ 73,150 Classified as: Cash equivalents 1 & 2 $ 15,514 Short-term debt securities 2 73,150 $ 88,664

Balance Sheet Components (Table

Balance Sheet Components (Tables)	6 Months Ended
	Jun. 30, 2023
Balance Sheet Related Disclosures [Abstract]
Schedule of Inventory	Inventories consist of the following (in thousands): June 30, December 31, Raw materials $ 279 $ 1,703 Work-in-progress 628 884 Finished goods 191 266 Total inventories $ 1,098 $ 2,853
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following (in thousands): June 30, December 31, Prepaid contract manufacturing costs $ 1,572 $ 3,542 Short term deposits 4,732 4,542 Prepaid research costs 3,355 2,822 Prepaid insurance 926 586 Prepaid marketing 343 753 Other 1,134 1,740 Total prepaid expenses and other current assets $ 12,062 $ 13,985
Schedule of Components of Accrued Liabilities	Accrued liabilities consist of the following (in thousands): June 30, December 31, Compensation and related benefits $ 3,925 $ 6,167 Contract research costs 1,559 4,188 Contract manufacturing costs 2,016 2,101 Product revenue reserves 1,831 1,373 Data hosting services 1,089 10 Legal fees 702 562 Other 324 1,254 Total accrued liabilities $ 11,446 $ 15,655

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Schedule of Long-Term Debt and Unamortized Discount Balances	Debt and unamortized discount balances are as follows (in thousands): June 30, December 31, Face value of debt $ 40,985 $ 40,531 Exit fee 2,600 2,600 Unamortized debt discount associated with exit fee, debt issuance costs and loan origination fees (3,236) (3,506) Total debt, net $ 40,349 $ 39,625

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock Option Activity	The following table summarizes stock option activity under the Company’s stock-based compensation plans during the six months ended June 30, 2023 (in thousands, except option and share data): Number of Weighted- Weighted- Aggregate Outstanding as of December 31, 2022 6,143,183 $ 9.00 6.00 $ — Granted 2,461,278 $ 1.44 Forfeited (1,267,693) $ 5.34 Outstanding as of June 30, 2023 7,336,768 $ 7.26 5.16 $ — Vested and exercisable as of June 30, 2023 4,606,523 $ 9.41 3.47 $ —
Weighted-Average Assumptions Used in Black-Scholes Model To Estimate Fair Value of Stock Options Granted	The fair value of stock options was estimated using the following weighted-average assumptions: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Expected term (in years) 6.02 6.08 5.15-6.08 5.27-6.08 Volatility 91.26%-92.98% 70.15%-71.20% 90.21%-93.48% 68.71%-71.20% Risk free interest rate 3.50%-4.05% 2.84%-3.03% 3.50%-4.22% 1.76%-3.03% Dividend yield — — — —
Schedule of Nonvested Restricted Stock Units and Performance Stock Units Activity and Weighted Average Grant Date Fair Value	The following table summarizes RSU and PSU activity and weighted average grant date fair value for the six months ended June 30, 2023: Shares Weighted- Unvested shares as of December 31, 2022 641,407 $ 7.08 Granted 54,167 $ 2.26 Vested (192,147) $ 5.12 Forfeited (202,019) $ 7.23 Unvested shares as of June 30, 2023 301,408 $ 7.36
Summary of Non-cash Stock Based Compensation Expense	Total stock-based compensation expense recognized was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Research and development $ 517 $ 820 $ 1,351 $ 1,445 Selling, general and administrative 228 1,388 1,936 2,810 Total $ 745 $ 2,208 $ 3,287 $ 4,255

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Maturity of Operating Leases Liabilities and Future Minimum Lease Payments	The maturities of the Company’s operating lease liabilities as of June 30, 2023 were as follows (in thousands): Undiscounted lease payments June 30, 2023 Remaining in 2023 $ 249 2024 84 2025 1 Total undiscounted payments 334 Less: imputed interest 12 Present value of future lease payments 322 Less: current portion of operating lease liabilities 321 Operating lease liabilities $ 1

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Summary of Potentially Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share	The following table sets forth the outstanding potentially dilutive securities which have been excluded in the calculation of diluted net loss per share because including such securities would be anti-dilutive (in common stock equivalent shares): Three Months Ended Six Months Ended 2023 2022 2023 2022 Options to purchase common stock 7,336,768 6,892,009 7,336,768 6,892,009 Restricted and Performance stock units (unvested) 301,408 818,019 301,408 818,019 ESPP 345,352 89,662 345,352 89,662 Total 7,983,528 7,799,690 7,983,528 7,799,690

Description of Business - Addit

Description of Business - Additional Information (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($) segment	Dec. 31, 2022 USD ($)	Jun. 30, 2022 USD ($)
Debt Instrument [Line Items]
Number of operating segments | segment	1
Cash, cash equivalents and short-term investments	$ 53,600
Cash and cash equivalents	22,983	$ 25,798
Debt securities, available-for-sale	30,600
Accumulated deficit	480,672	437,193
Face value of term loan	40,985	$ 40,531
Secured Debt, Tranche B | Innovatus Loan | Line of Credit
Debt Instrument [Line Items]
Face value of term loan	$ 17,500		$ 17,500

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Product Information [Line Items]
Aggregated transaction gains (losses)		$ (29,000)			$ 26,000
Foreign currency translation adjustment		13,000	$ (37,000)	$ 0	(24,000)	$ 0
Accounts receivable, allowance for doubtful accounts		0			0		$ 0
Bad debt expense					0	0
Inventory write down		0		0	10,000	0
Early access program term (in years)	1 year
Product revenue, net		$ 4,643,000		$ 4,091,000	$ 8,761,000	$ 6,764,000
Customer A | Financing Receivable | Customer Concentration Risk
Product Information [Line Items]
Concentration risk					63%		58%
Customer A | Revenue Benchmark | Customer Concentration Risk
Product Information [Line Items]
Concentration risk		78%		99%	77%	100%
Customer A | Accounts Payable | Customer Concentration Risk
Product Information [Line Items]
Concentration risk					43%		12%
Customer B | Financing Receivable | Customer Concentration Risk
Product Information [Line Items]
Concentration risk					37%		42%
Customer B | Revenue Benchmark | Customer Concentration Risk
Product Information [Line Items]
Concentration risk		22%			23%
Customer B | Accounts Payable | Customer Concentration Risk
Product Information [Line Items]
Concentration risk					12%		11%
Customer C | Accounts Payable | Customer Concentration Risk
Product Information [Line Items]
Concentration risk					11%
Product revenue, net
Product Information [Line Items]
Product revenue, net		$ 4,393,000		$ 3,341,000	$ 8,511,000	$ 6,014,000
Autorisation Temporaire D Utlisation Member
Product Information [Line Items]
Product revenue, net		$ 100,000		$ 0	$ 600,000	$ 0

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	$ 50,923,000	$ 50,923,000	$ 88,664,000
Financial liabilities	0	0	0
Other-than-temporary impairment losses	0	0
Unrealized gain (loss)	(40,000)	(40,000)
Unrealized loss position for more than 12 months	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0	0	0
Financial liabilities	$ 0	0	0
Transfers in or out of level 3		$ 0	$ 0

Fair Value Measurements - Estim

Fair Value Measurements - Estimated Value of Cash Equivalents and Debt Securities and Gross Unrealized Holding Gains and Losses (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Cash Equivalents and Investment Securities [Line Items]
Cash equivalents, amortized cost	$ 20,297	$ 15,514
Cash equivalents, estimated fair value	20,297	15,514
Debt securities, amortized cost	30,666	73,350
Debt securities, unrealized gain	0	3
Debt securities, unrealized loss	40	203
Debt securities, estimated fair value	30,626	73,150
Assets, fair value	50,923	88,664
Corporate debt securities | Level 2
Cash Equivalents and Investment Securities [Line Items]
Debt securities, amortized cost	3,998	28,759
Debt securities, unrealized gain	0	0
Debt securities, unrealized loss	1	117
Debt securities, estimated fair value	3,997	28,642
Commercial paper | Level 2
Cash Equivalents and Investment Securities [Line Items]
Debt securities, amortized cost		4,945
Debt securities, unrealized gain		0
Debt securities, unrealized loss		0
Debt securities, estimated fair value		4,945
U.S. government bonds | Level 2
Cash Equivalents and Investment Securities [Line Items]
Debt securities, amortized cost	26,668	39,646
Debt securities, unrealized gain	0	3
Debt securities, unrealized loss	39	86
Debt securities, estimated fair value	26,629	39,563
Short-term debt securities | Level 2
Cash Equivalents and Investment Securities [Line Items]
Debt securities, estimated fair value	30,626	73,150
Money market funds | Level 1
Cash Equivalents and Investment Securities [Line Items]
Cash equivalents, amortized cost	20,297	11,546
Cash equivalents, estimated fair value	20,297	11,546
Cash equivalents | Level 1
Cash Equivalents and Investment Securities [Line Items]
Cash equivalents, estimated fair value	$ 20,297
Cash equivalents | Level 1 and 2
Cash Equivalents and Investment Securities [Line Items]
Cash equivalents, estimated fair value		15,514
Commercial paper | Level 2
Cash Equivalents and Investment Securities [Line Items]
Cash equivalents, amortized cost		3,968
Cash equivalents, estimated fair value		$ 3,968

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 279	$ 1,703
Work-in-progress	628	884
Finished goods	191	266
Total inventories	$ 1,098	$ 2,853

Balance Sheet Components - Sc_2

Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Balance Sheet Related Disclosures [Abstract]
Prepaid contract manufacturing costs	$ 1,572	$ 3,542
Short term deposits	4,732	4,542
Prepaid research costs	3,355	2,822
Prepaid insurance	926	586
Prepaid marketing	343	753
Other	1,134	1,740
Total prepaid expenses and other current assets	$ 12,062	$ 13,985

Balance Sheet Components - Sc_3

Balance Sheet Components - Schedule of Components of Accrued Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Balance Sheet Related Disclosures [Abstract]
Compensation and related benefits	$ 3,925	$ 6,167
Contract research costs	1,559	4,188
Contract manufacturing costs	2,016	2,101
Product revenue reserves	1,831	1,373
Data hosting services	1,089	10
Legal fees	702	562
Other	324	1,254
Total accrued liabilities	$ 11,446	$ 15,655

Bristol-Meyers Squibb License_2

Bristol-Meyers Squibb License Agreement - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended
	Mar. 31, 2022	Apr. 30, 2016	Jun. 30, 2022	Mar. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Value of common stock issued during period			$ 20,564	$ 45,610
Common Stock
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Issuance of common stock (in shares)			2,686,288	5,841,786
Value of common stock issued during period			$ 2	$ 6
Licensing Agreements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Up front cash payments		$ 2,000
BMS Transaction | Common Stock | Purchase Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Issuance of common stock (in shares)		157,587
Value of common stock issued during period		$ 3,200
BMS Transaction | Licensing Agreements | Development And Regulatory Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone obligations		61,000
BMS Transaction | Licensing Agreements | Commercial Sales | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone obligations		128,000
BMS Transaction | Licensing Agreements | Development Phase Two [Domain]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone obligations		$ 3,000
BMS Transaction | Licensing Agreements | Development Phase Three
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone obligations	$ 5,000

Debt - Additional Information (

Debt - Additional Information (Detail) $ / shares in Units, $ in Thousands		3 Months Ended			6 Months Ended
	Jun. 01, 2022 USD ($) tranche $ / shares shares	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($) tranche	Mar. 31, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($) tranche	Dec. 31, 2022 USD ($)
Debt Instrument [Line Items]
Face value of term loan		$ 40,985			$ 40,985		$ 40,531
Interest expense		1,343	$ 934		2,628	$ 1,820
Issuance of common stock			20,564	$ 45,610
Loss on extinguishment of debt					0	1,144
Line of Credit | Secured Debt | Innovatus Stock Purchase Agreement
Debt Instrument [Line Items]
Issuance of common stock	$ 5,000
Sale of common stock, shares issued (in shares) | shares	749,053
Sale of common stock (in USD per share) | $ / shares	$ 6.6751
Line of Credit | Innovatus Loan | Secured Debt
Debt Instrument [Line Items]
Loan agreement, aggregate borrowing capacity	$ 75,000
Number of tranches | tranche	3
Debt Instrument, percent of interest due (in percent)	0.0225
Interest due timeframe	3 years
Percentage of exit fee on principal balance	6.50%
Minimum cash balance of face value of loan (in percent)	0.05
Debt discount		200			200
Capitalized debt issuance costs		1,100			1,100
Interest expense		1,300			$ 2,600
Effective interest rate					13.60%
Line of Credit | Innovatus Loan | Secured Debt | Variable Rate Component One | Minimum
Debt Instrument [Line Items]
Minimum prime rate	3.50%
Line of Credit | Innovatus Loan | Secured Debt | Variable Rate Component Two
Debt Instrument [Line Items]
Minimum prime rate	3.75%
Line of Credit | Innovatus Loan | Secured Debt, Tranche A
Debt Instrument [Line Items]
Face value of term loan			40,000			40,000
Line of Credit | Innovatus Loan | Secured Debt, Tranche B
Debt Instrument [Line Items]
Face value of term loan		$ 17,500	$ 17,500		$ 17,500	$ 17,500
Line of Credit | Innovatus Loan | Secured Debt, Tranche B And C
Debt Instrument [Line Items]
Number of tranches | tranche			2			2
Face value of term loan			$ 35,000			$ 35,000
Line of Credit | Oxford Loan | Secured Debt
Debt Instrument [Line Items]
Face value of term loan	$ 33,500
Line of Credit | Amended Oxford Loan | Amended Tranche A
Debt Instrument [Line Items]
Loan agreement, aggregate borrowing capacity	30,000
Accrued and unpaid interest	200
Other final payments	3,300
Repayments of loan agreement exit fee	$ 33,500
Loss on extinguishment of debt			$ 1,100

Debt - Schedule of Long-Term De

Debt - Schedule of Long-Term Debt and Unamortized Discount Balances (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Face value of debt	$ 40,985	$ 40,531
Exit fee	2,600	2,600
Unamortized debt discount associated with exit fee, debt issuance costs and loan origination fees	(3,236)	(3,506)
Total debt, net	$ 40,349	$ 39,625

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	May 31, 2023 USD ($) employee	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2022 USD ($) $ / shares shares	Feb. 06, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock available for grant (in shares) | shares			30,000		30,000
Stock-based compensation expense		$ 745	$ 2,208	$ 3,287	$ 4,255
Number of employees terminated | employee	4
Total unrecognized compensation expense		$ 6,100		$ 6,100
Weighted-average period for recognition (in years)				2 years 9 months 18 days
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average grant date fair value of employee option grants (in USD per share) | $ / shares		$ 1.03	$ 4.39	$ 1.44	$ 3.53
Restricted Stock Units (RSU)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock available for grant (in shares) | shares		0	0	39,167	298,150
Weighted-average grant date fair value of employee stock award grants (in USD per share) | $ / shares				$ 2.26	$ 5.22
Stock-based compensation expense		$ 100	$ 500	$ 500	$ 900
Total unrecognized compensation expense		$ 1,400		$ 1,400
Weighted-average period for recognition (in years)				1 year 8 months 12 days
Performance Stock Units (PSU)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock available for grant (in shares) | shares		0		15,000
Weighted-average grant date fair value of employee stock award grants (in USD per share) | $ / shares			$ 6.87	$ 2.26	$ 6.87
Stock-based compensation expense		$ 200		$ 100
Vested (in shares) | shares			0	0	0
Total unrecognized compensation expense		1,400		$ 1,400
Weighted-average period for recognition (in years)				1 year 8 months 12 days
Performance Stock Units (PSU) | Four Terminated Employees
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock compensation recognized (reversed)	$ (400)
Performance Stock Units (PSU) | Accelerated Vesting
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vested (in shares) | shares				15,000
Unvested Stock Options, Performance-Based Restricted Stock Units, And Time-Based RSUs | Former CEO
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock compensation recognized (reversed)		$ 0			$ 900
Accelerated vesting						0.50
Restated 2013 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available to be issued (in shares) | shares		3,134,441		3,134,441
Inducement Plan 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available to be issued (in shares) | shares		1,495,000		1,495,000

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Number of Options
Number of options, outstanding, beginning balance (in shares)	6,143,183
Number of options, granted (in shares)	2,461,278
Number of options, forfeited (in shares)	(1,267,693)
Number of options, outstanding, ending balance (in shares)	7,336,768	6,143,183
Number of options, vested and exercisable (in shares)	4,606,523
Weighted- Average Exercise Price
Weighted-average exercise price, outstanding, beginning balance (in USD per share)	$ 9
Weighted-average exercise price, granted (in USD per share)	1.44
Weighted-average exercise price, forfeited (in USD per share)	5.34
Weighted-average exercise price, outstanding, ending balance (in USD per share)	7.26	$ 9
Weighted-average exercise price, vested and exercisable (in USD per share)	$ 9.41
Stock Options Additional Disclosures
Weighted average remaining contractual life, beginning balance (in years)	5 years 1 month 28 days	6 years
Aggregate intrinsic value, beginning balance	$ 0
Weighted average remaining contractual life, ending balance (in years)	5 years 1 month 28 days	6 years
Aggregate intrinsic value, ending balance	$ 0	$ 0
Weighted average remaining contractual life, vested and exercisable (in years)	3 years 5 months 19 days
Aggregate intrinsic value, vested and exercisable	$ 0

Stock-Based Compensation - Weig

Stock-Based Compensation - Weighted-Average Assumptions Used In Black-Scholes Model To Estimate Fair Value of Stock Options Granted (Detail) - Stock Options	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years 7 days	6 years 29 days
Volatility, minimum	91.26%	70.15%	93.48%	68.71%
Volatility, maximum	92.98%	71.20%	90.21%	71.20%
Risk free interest rate, minimum	3.50%	2.84%	3.50%	1.76%
Risk free interest rate, maximum	4.05%	3.03%	4.22%	3.03%
Dividend yield	0%	0%	0%	0%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)			5 years 1 month 24 days	5 years 3 months 7 days
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)			6 years 29 days	6 years 29 days

Stock Based Compensation - Sche

Stock Based Compensation - Schedule of Nonvested Restricted Stock Units and Performance Stock Units Activity and Weighted Average Grant Date Fair Value (Detail) - $ / shares	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
RSU and PSU Roll Forward Activity
Stock options granted (in shares)	30,000		30,000
Restricted Stock Units and Performance Stock Unit
RSU and PSU Roll Forward Activity
Unvested shares, beginning balance (in shares)		641,407
Stock options granted (in shares)		54,167
Vested (in shares)		(192,147)
Forfeited (in shares)		(202,019)
Unvested shares, ending balance (in shares)		301,408
Weighted-Average
Weighted average grant-date fair value of options beginning balance (in USD per share)		$ 7.08
Weighted-average grant date fair value of employee stock award grants (in USD per share)		2.26
Weighted average grant-date fair value of options vested (in USD per share)		5.12
Weighted average grant-date fair value of options forfeited (in USD per share)		7.23
Weighted average grant-date fair value of options ending balance (in USD per share)		$ 7.36

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Non-cash Stock Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 745	$ 2,208	$ 3,287	$ 4,255
Research and development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	517	820	1,351	1,445
Selling, general and administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 228	$ 1,388	$ 1,936	$ 2,810

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 2,000	$ 17,000	$ 4,000	$ 26,000
Effective tax rate			(0.01%)	(0.06%)

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Feb. 28, 2023	Dec. 31, 2022	Nov. 15, 2022 claim	Nov. 08, 2022 executive	Oct. 31, 2017 USD ($) ft²
Other Commitments [Line Items]
Rent expense recognized for company's operating leases	$ 100	$ 100	$ 300	$ 300
Variable lease payments for operating leases	$ 23	$ 23	38	46
Operating cash outflows for operating lease liabilities			$ 300	$ 300
Weighted-average remaining lease term (in years)	8 months 12 days		8 months 12 days			1 year 2 months 12 days
Weighted-average discount rate (in percent)	12.82%		12.82%			12.82%
Number of former executives | executive								2
Number of claims | claim							2
Palo Alto, California
Other Commitments [Line Items]
Total leased space | ft²									8,029
Lease renewal term					1 year				3 years
Renewal extension term					1 year
Security deposit									$ 300

Commitments and Contingencies_2

Commitments and Contingencies - Maturity of Operating Leases Liabilities and Future Minimum Lease Payments (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Leases [Abstract]
Remaining in 2023	$ 249
2024	84
2025	1
Total undiscounted payments	334
Less: imputed interest	12
Present value of future lease payments	322
Less: current portion of operating lease liabilities	321	$ 491
Operating lease liabilities	$ 1	$ 83

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Potentially Dilutive Shares Excluded from Computation of Diluted Net (Loss) Income Per Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities	7,983,528	7,799,690	7,983,528	7,799,690
Options to purchase common stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities	7,336,768	6,892,009	7,336,768	6,892,009
Restricted and Performance stock units (unvested)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities	301,408	818,019	301,408	818,019
ESPP
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities	345,352	89,662	345,352	89,662